ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Summary

This is an open-label dose escalation study designed to evaluate the safety and pharmacokinetics of ABBV-085 and determine the recommended Phase 2 dose (as monotherapy or in combination with standard therapies) in subjects with advanced solid tumors.

Timeline

Start

2015-09-18

Primary completion

2019-03-25

Completion

2019-03-25

Publications

• Ray U, Pathoulas CL, Thirusangu P, Purcell JW, Kannan N, Shridhar V. Exploiting LRRC15 as a Novel Therapeutic Target in Cancer. Cancer Res. 2022 May 3;82(9):1675-1681. doi: 10.1158/0008-5472.CAN-21-3734.

Drugs

Indications